A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation - Summary - MDSpire
Advertisement
A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation
To establish and validate a predictive model for identifying AChR-MG patients likely to achieve minimal symptom expression (MSE) after low-dose rituximab treatment.
Key Findings:
117 patients were included in the study.
Five variables were identified as significant predictors: new-onset MG, baseline MG-ADL score, high CD19+/CD27+ B lymphocyte proportion, high-dose prednisone, and early immunotherapy initiation.
The model demonstrated moderate discriminative ability with an AUC of 0.777, indicating its effectiveness in distinguishing between outcomes.
Using a threshold probability of 0.534, sensitivity was 72.7% and specificity was 71.0%.
The high-probability group had a 6.52-fold higher likelihood of achieving MSE.
Interpretation:
The nomogram aids in identifying AChR-MG patients who are likely to attain MSE after low-dose rituximab, facilitating personalized treatment decisions.
Limitations:
The study is retrospective and conducted at a single center, which may limit generalizability.
The sample size may not be sufficient to fully validate the predictive model.
Conclusion:
The developed nomogram supports targeted application of low-dose rituximab in AChR-MG patients, enhancing treatment personalization.
